TauroLock™

• dialysis
• oncology
• parenteral nutrition
• intensive care 

• 1.35 % taurolidine: broad antimicrobial activity against bacteria and fungi without generating resistance
• 4 % citrate: anticoagulant to maintain patency 

• prevention of biofilm
• prevention of occlusion
• prevention of infection

• single dose: 3 ml or 5 ml ampoules (10 per box)
• multiple dose: 10 ml vials (100 per box) 
• store between 15 and 30 °C (do not freeze)
  

Cost analysis 2023

“[TauroLock™] in the primary prevention of CRBSIs [catheter-related bloodstream infections] in patients with CIF [chronic intestinal failure] receiving HPN [home parenteral nutrition] is associated with reduced hospital costs and infection rates.” 

Williams et al. JPEN J Parenter Enteral Nutr 2023. DOI: 10.1002/jpen.2589    

Clinical study 2019

“[TauroLock™] is a safe and cost-effective method for the prevention of CRIs [catheter-related infections] in very young children.” 

Łyszkowska et al. J Hosp Infect 2019. DOI: 10.1016/j.jhin.2019.04.022   

Clinical study 2008

“TauroLock™ … as standard lock solution in long-term CVADs [central-venous access devices] significantly reduced the incidence density of CVAD-associated infections due to CoNS or MRSE.”  

Simon et al. BMC Infect Dis 2008. DOI: 10.1186/1471-2334-8-102  

Clinical study 2004

“[TauroLock™] is effective and safe for the prevention of CRS [catheter-related sepsis]. It may lead to a sizeable reduction in CRS incidence, even in a dialysis centre where CRS incidence is already low using heparin.” 

Betjes et al. Nephrol Dial Transplant 2004. DOI: 10.1093/ndt/gfh014